Fatty liver disease

Long before I ever set foot inside my gastroenterologist’s office to discuss my liver health and metabolic dysfunction-associated steatohepatitis (MASH), I was diagnosed with…

Belapectin, Galectin Therapeutics’ investigational therapy, significantly reduced the development of new enlarged blood vessels in the esophagus among people with metabolic dysfunction-associated steatohepatitis (MASH),…

Your liver may store excess fat when you’re living with metabolic dysfunction-associated steatohepatitis (MASH), but does it also store secrets you’re keeping from your…

Madrigal Pharmaceuticals has secured worldwide rights to develop ARO-PNPLA3, an experimental treatment created by Arrowhead Pharmaceuticals for people with metabolic dysfunction-associated steatohepatitis (MASH),…

The email wasn’t unexpected. Earlier in the week, I had received a call from my transplant coordinator at one of the two hospitals where I’m…

A once-monthly investigational therapy for metabolic dysfunction-associated steatohepatitis (MASH), called efimosfermin, has earned two new regulatory designations — one in the U.S. and the other…

One of the things I’ve been most grateful for over the past few years is simple: I’m not as sick as I once was. When…

Clearing senescent macrophages, a type of damaged immune cell that doesn’t die off as it should, reduced inflammation and reversed signs of liver fat buildup…

As much as I’d like to believe the tough people who say they have “no regrets,” I’m not buying it. You mean to…

A Phase 2 clinical trial testing Rivus Pharmaceuticals‘ experimental oral therapy HU6 in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of…